{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Lutetium_Lu_177_DOTA-Tetulomab",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A radioimmunoconjugate, which consists of a monoclonal antibody against the cell-surface antigen CD37 covalently linked, via the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. The antibody moiety of lutetium Lu 177 DOTA-tetulomab binds to CD37 on tumor B-cells. Upon internalization, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.",
    "fdaUniiCode": "CPW7BR9UY7",
    "identifier": "C105403",
    "preferredName": "Lutetium Lu 177 DOTA-Tetulomab",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129819",
      "C2124"
    ],
    "synonyms": [
      "177Lu-DOTA-HH1",
      "177Lu-Dota-Tetulomab",
      "177Lu-HH1",
      "Lutetium Lu 177 DOTA-Tetulomab",
      "TETULOMAB TETRAXETAN LU-177"
    ]
  }
}